Adjust Font Sizing:

Blog Post

January is Mental Wellness Month

What is mental wellness? According to the World Health Organization, mental wellness is “a state of well-being in which the individual realizes his or her own abilities, can cope […]

10 ways to manage stress this winter

With shorter periods of daylight and cold weather, winter can make living with narcolepsy, idiopathic hypersomnia, and related health issues even more challenging. This is why getting […]

Staff Update

Those of you who attended the highly successful 36th Annual Narcolepsy Network Conference in Atlanta will already know that our Transition Director Amy Kant was unable to […]

Stay Hydrated This Summer

While exposure to light is supposed to promote “alertness”, it’s not uncommon to feel tired or even sluggish after spending time outside. There are many factors that […]

Listening Journey: Our Collective Voice Matters

Last year, Narcolepsy Network began a “Listening Journey” to better understand our organization’s individual and collective interests. We also sought out the perspectives of medical professionals and industry […]

Clinical Research Matters: Takeaways From World Sleep Congress 2022

by Keith Harper, Board President Last week, Amy Kant, Transition Director, and I traveled to Rome for the 2022 World Sleep Congress, an event put together by […]

ROME: World Sleep 2022

We are excited to announce that we will be attending World Sleep 2022, in Rome, Italy, from March 14-16. The World Sleep congress, now in its 16th iteration, […]

Narcolepsy Advocacy Program Workshop

Our first virtual Narcolepsy Advocacy Program Workshop was a huge success, training more than 30 youth and young adults. Narcolepsy Network will be hosting additional workshops throughout […]

Avadel Pharmaceuticals Announces Results from its Phase 3 Trial of Once-Nightly FT218

Avadel Pharmaceuticals plc (Nasdaq: AVDL) announced positive topline data from its pivotal Phase 3 REST-ON trial assessing the safety and efficacy of FT218, an investigational, once-nightly formulation […]

Jazz Pharmaceuticals Announce the FDA Acceptance of New Drug Application for JZP-258

Jazz Pharmaceuticals plc announced that the US Food and Drug Administration (FDA) accepted for filing with Priority Review the company’s New Drug Application seeking marketing approval for […]